DSM, Crucell see 15gl-1 yield with PER.C6

Reuters

EMEA expects record year

The European Medicines Agency (EMEA) expects a record number of applications for market approval in 2008, according to its annual report. The Agency expects to surpass the record number of positive opinions issued in 2007.
Pharma Times

Evonik puts IPO on hold

Bloomberg

Lonza manufactures clinical trial material for iCo Therapeutics

iCo Therapeutics

Explosion at Synthetech facility

Albany Democrat Herald

SOCMA opposes IST legislation

Joe Acker, president of the Synthetic Organic Chemical Manufacturers Association (SOCMA), said his trade group is “stridently opposed to the merits of mandating inherently safer technology under the guise of site security”. Acker's comments follow the approval by the House Committee on Homeland Security approved the “Chemical Facility Anti-Terrorism Act of 2008" which includes the inherently safer technology (IST) reporting requirement.
ICIS

Link Technologies opens new kilo-scale facilities

Link Technologies

Evonik acquires in China

Evonik has acquired the remaining 49% of its former joint venture Degussa Lynchem Co. Ltd., Dalian, China, from the Chinese shareholders Yuncai Wang and Jingkun Wang. Degussa Lynchem has become a wholly owned subsidiary of Evonik.
Degussa

10 bidders lined up for Evonik

Reuters

Hovione invests in China

Hovione has purchased 75% of Hisyn Pharmaceutical Co. Limited, based in Zhejiang. Hovione said the acquisition provides it with significant additional drug substance manufacturing production capacity and strengthens its 20 year presence in China. The acquisition includes development labs and a 22,000m² API) plant, which will now produce Hovione's two largest volume products.
PR Newswire

Merck invests in research centre

Merck KGaA will spend €47m on a new research centre at its Darmstadt headquarters. The centre will bring together the research activities of the liquid crystal and performance and life science chemicals businesses. Construction will begin in June and inauguration is planned for the end of 2009.
CNN

Eden in manufacturing deal with Stealthyx

Eden Biodesign will produce Stealthyx Therapeutics' lead therapeutic candidate. Stealthyx is evaluating for treatment of a range of inflammatory diseases including rheumatoid arthritis.
Eden Biodesign

Hikal to supply active ingredients for Bayer CropScience

Reuters

Pfizer plans more outsourcing to keep costs down

Business Week

GAO to investigate FDA approval process

CNBC

DSM sells Special Products unit to Arsenal Capital Partners

Financial news

Cambrex contests fire and explosion fines

WCF Courier

FDA needs more funds

The Leaders of the US Committee on Energy and Commerce have said that the FDA needs an injection of funds seven times that proposed by President Bush in his budget.
Committee on Energy and Commerce

China says: buyer beware

China's State Food and Drug Administration (SFDA) said that the ultimate responsibility for imported drug ingredients lies with the importing country.
Lab Technologist

Cobra in SARS protein deal

Cobra Biomanufacturing will carry out downstream processing for a protein from the SARS virus for an undisclosed pharmaceutical company. The protein will be manufactured by the pharma partner and will be used in phase I trails.
Cobra